![conference banner](/images/conference-banner.jpeg)
Abstract
Amyloid beta (Aβ), especially Aβ oligomers, is important in early Alzheimer’s disease (AD) pathogenesis. AD-associated inflammation has generally been considered as a secondary response to the pathological lesions evoked by Aβ oligomers in the early stage of pathogenesis. We studied the levels of plasma Aβ monomers, Aβ oligomers, and soluble tumor necrosis factor α receptors (sTNFRs) in 120 controls, 32 amnestic mild cognitive impairment (aMCI) patients, and 90 mild AD patients. The plasma Aβ monomer, oligomer and sTNFR levels were measured by ELISA. We observed that the Aβ oligomer levels in mild AD patients were significantly higher than those in aMCI (200.8±83.8 versus 93.9±23.3, P<0.05) and healthy subjects (200.8±83.8 versus 70.0±60.9, P<0.05). The sTNFR levels in the plasma of aMCI and mild AD patients were significantly higher than the levels of control subjects. Moreover, the levels of both sTNFR1 and sTNFR2 were significantly correlated with Aβ oligomer levels in aMCI (sTNFR1r= 0.376, P= 0.034; sTNFR2r= 0.367, P= 0.039) and mild AD patients (sTNFR1r= 0.471, P< 0.001; sTNFR2 r= 0.407, P< 0.001). More importantly, changes in Aβ oligomer and sTNFR levels accurately differentiated mild AD patients from control subjects, supporting these levels might be potential diagnostic biomarkers for aMCI and AD.
Keywords: Alzheimer's disease, amyloid-beta oligomers, biomarker, ELISA, soluble tumor necrosis factor receptor.
Current Alzheimer Research
Title:Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD
Volume: 11 Issue: 4
Author(s): Jinbiao Zhang, Mao Peng and Jianping Jia
Affiliation:
Keywords: Alzheimer's disease, amyloid-beta oligomers, biomarker, ELISA, soluble tumor necrosis factor receptor.
Abstract: Amyloid beta (Aβ), especially Aβ oligomers, is important in early Alzheimer’s disease (AD) pathogenesis. AD-associated inflammation has generally been considered as a secondary response to the pathological lesions evoked by Aβ oligomers in the early stage of pathogenesis. We studied the levels of plasma Aβ monomers, Aβ oligomers, and soluble tumor necrosis factor α receptors (sTNFRs) in 120 controls, 32 amnestic mild cognitive impairment (aMCI) patients, and 90 mild AD patients. The plasma Aβ monomer, oligomer and sTNFR levels were measured by ELISA. We observed that the Aβ oligomer levels in mild AD patients were significantly higher than those in aMCI (200.8±83.8 versus 93.9±23.3, P<0.05) and healthy subjects (200.8±83.8 versus 70.0±60.9, P<0.05). The sTNFR levels in the plasma of aMCI and mild AD patients were significantly higher than the levels of control subjects. Moreover, the levels of both sTNFR1 and sTNFR2 were significantly correlated with Aβ oligomer levels in aMCI (sTNFR1r= 0.376, P= 0.034; sTNFR2r= 0.367, P= 0.039) and mild AD patients (sTNFR1r= 0.471, P< 0.001; sTNFR2 r= 0.407, P< 0.001). More importantly, changes in Aβ oligomer and sTNFR levels accurately differentiated mild AD patients from control subjects, supporting these levels might be potential diagnostic biomarkers for aMCI and AD.
Export Options
About this article
Cite this article as:
Zhang Jinbiao, Peng Mao and Jia Jianping, Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD, Current Alzheimer Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567205011666140317103222
DOI https://dx.doi.org/10.2174/1567205011666140317103222 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cost of Treatment and Care for People with Alzheimer’s Disease: A Meta- Analysis
Current Alzheimer Research Adenosine A1 Receptor: Analysis of the Potential Therapeutic Effects Obtained by its Activation in the Central Nervous System
Current Medicinal Chemistry Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Quorum-Sensing Inhibitors and Biofilms
Anti-Infective Agents in Medicinal Chemistry Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Micromorphology of the Yellow Cuticle in Social Wasps: The Presence of Rhabdomeric and Ciliary Peripheral Photoreceptors
Current Nanoscience The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Type 2 Diabetes Mellitus in Saudi Arabia: Major Challenges and Possible Solutions
Current Diabetes Reviews Development of Pin1 Inhibitors and their Potential as Therapeutic Agents
Current Medicinal Chemistry An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis
Medicinal Chemistry Zn(L-proline)2: An Efficient and Recyclable Catalytic System for the Asymmetric Multicomponent Synthesis of 2-amino-4H-chromenes in Water Under Controlled Microwave Heating
Current Microwave Chemistry The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors
Current Pharmaceutical Design Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials Current and Under Development Treatment Modalities of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Adaptation to Traumatic Stress: Resilient Traits, Resources, and Trajectories of Outcomes
Current Psychiatry Reviews Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis
Current Pharmaceutical Design